Scalper1 News
Big biotech Gilead Sciences (GILD) soundly beat analysts’ Q3 expectations and raised its guidance yet again Tuesday, though the stock slipped about 1% in after-hours trading. Gilead’s earnings, excluding one-time items, jumped 75% over the year-earlier quarter to $3.22 a share, beating analysts’ consensus by 35 cents, according to Thomson Reuters. Revenue climbed 37% to $8.3 billion, topping Wall Street’s average estimate by nearly $500 million. Scalper1 News
Scalper1 News